WuXi Biologics (Cayman) Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
WXXWY Over the counter 2830 www.wuxibiologics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for WuXi Biologics (Cayman) Inc.

WuXi Biologics Receives Top-Honor Jade Award at The Asset Corporate Sustainability Leadership Awards 2026 - Oct 21st, 2026 12:44 am
Can WuXi Biologics (Cayman) (SEHK:2269) Stay Reasonable As Capacity Expands? - Oct 20th, 2026 11:12 am
WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence - Oct 14th, 2026 5:36 am
Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption - Oct 1st, 2026 2:02 am
WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability - Sep 24th, 2026 6:47 am
WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership - Sep 16th, 2026 2:57 am
Big Pharma Is Pouring Billions Into China’s Biotechs - Sep 14th, 2026 1:59 am
WuXi Biologics Reports Strong Profitable Growth in H1 2026 - Aug 25th, 2026 6:45 am
WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO - Aug 18th, 2026 1:04 am
Vertex Autoimmune Deal With WuXi Adds New Angle To VRTX Valuation Story - Feb 14th, 2026 11:09 pm
Vertex Partners With WuXi To Broaden Autoimmune Pipeline Beyond Cystic Fibrosis - Feb 10th, 2026 4:07 am